Microdosing vs. Therapeutic Dosing for Evaluation of Pharmacokinetic Data: A Comparative Study

ABSTRACT

Objectives: Human microdosing studies or phase 0 studies have been proposed to supplement pharmacokinetic (PK) studies in animals. In phase 0 studies, extremely low, nonpharmacologically active doses of a drug are given to a few subjects before phase 1, to deÞ ne the agent’s PK proÞ le in humans. This study has been conducted to compare the values of different PK parameters, as determined by microdosing and conventional therapeutic dose studies in healthy volunteers, and target patient population. Materials and Methods:In the Þ rst phase of study, 30 healthy adult male volunteers were divided into three groups of 10 each; receiving 14C-labelled atenolol, enalapril and losartan orally, in single microdose. After a wash-out period of 10 days, the same individual received the same drug in single therapeutic dose. In second phase of study, 30 hypertensive patients were divided into three groups and given same drugs. Parameters studied were t½, AUC, Cmax and tmax. Blood samples collected at intervals were subjected to accelerator mass spectrometry (AMS) and high performance liquid chromatography (HPLC), for microdosing and therapeutic dose studies respectively. Results:Microdosing results were comparable with therapeutic dose values for all the drugs studied and showed linearity over therapeutic dose. Conclusions:Microdosing PK parameters are comparable to the ones determined by therapeutic dose studies up to a permissible limit. So the idea of phase 0 PK studies supplementing phase 1 PK studies can be furthered.

KEYWORDS

• Microdosing
• Phase I studies
• pharmacokinetics
• therapeutic dose

Showing references and in-text citations exactly as published.

• DOI10.4103/0975-1483.59315Copy

RELATED ARTICLES

Matched on section and article type within this issue of JYP.

• Article · VOLUME 1, ISSUE 4Effect of Permeation Enhancers on the Release and Permeation Kinetics of Oxytetracycline Hydrochloride Organogel FormulationsNandini D, Chauhan NS, Chandra A, Pathak K · pp. 285–289PharmaceuticsSame type: Article
• Article · VOLUME 1, ISSUE 4Advanced PEGylation for the Development of Raloxifene Hydrochloride, BCS Class II DrugBandela JJ, Anupama CH · pp. 295–300PharmaceuticsSame type: Article
• Article · VOLUME 1, ISSUE 4Development and Evaluation of Sustained Delivery of Diclofenac Sodium from Hydrophilic Polymeric BeadsDhanaraju MD, Sundar VD, NandhaKumar S, Bhaskar K · pp. 301–304PharmaceuticsSame type: Article
• Article · VOLUME 1, ISSUE 4Design, Evaluation and Study of Effect of Hydrophilic Polymers on Release Rate of Antiulcer Floating TabletsAkbari BV, Dholakiya RB, Shiyani BG, Lodhiya DJ, Shastry CS · pp. 305–311PharmaceuticsSame type: Article